Morphosys Ag's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Morphosys Ag (MOR) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Morphosys Ag vs Its Competitors
- TTM: Trailing 12-month revenue of 258M vs 698,258M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+314.2% annualized vs trailing 12 months), vs accelerating (+46.3%) for its tracked peer group.
- Growth: Morphosys Ag generated -14.4% revenue growth year over year in Q4 2023, vs 0.6% for its tracked competitors combined.
- Profitability: Its -79.6% net margin compares with 13.9% for the peer group.
- Peer revenue share: Morphosys Ag accounted for 0.1% of combined revenue among its tracked peer group, down from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.50M compares with $1.00M for the peer group (0.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MOR Sales vs. its Competitors, Q4 2023
Morphosys Ag reported revenue contraction of 14.37 % year on year in Q4 2023, below its competitors' combined revenue growth of 0.58 %.
With a net margin of -79.63 %, Morphosys Ag reported lower profitability than its competitors (13.88 %).
Morphosys Ag generated 0.10 % of the combined sales of its peer group, down from 0.12 % a year earlier.
Morphosys Ag vs. its Competitors, Q4 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Morphosys Ag and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Morphosys Ag | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Morphosys Ag's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs -14.4% for Morphosys Ag. Morphosys Ag's share of combined industry revenue moved from 0.07% to 0.05%, a loss of 0.01 percentage points.
Morphosys Ag's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Morphosys Ag | No | No | No | No |
| Competitors combined (180) | ||||
| High-Confidence Competitors (1) | - | - | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MOR Stock Performance relative to its Competitors
MOR Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Gt Biopharma Inc | 282.9% | Outperformed |
| 2 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
| 3 | Spyre Therapeutics Inc | 282.9% | Outperformed |
| 4 | Damora Therapeutics Inc | 282.9% | Outperformed |
| 5 | Gossamer Bio Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Morphosys Ag's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Morphosys Ag's Comment on Competition and Industry Peers
Publicly Traded Peers of Morphosys Ag
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Morphosys Ag | 650.57 | 257.74 |
| Akari Therapeutics Plc | 1,104,440.22 | - |
| Eli Lilly And Company | 1,034,082.40 | 79,665.80 |
| Johnson and Johnson | 645,992.07 | 97,929.00 |
| Beone Medicines Ltd | 550,872.13 | 6,128.24 |
| Abbvie Inc | 463,275.89 | 64,386.00 |
| SUBTOTAL | 6,038,347.72 | 735,430.48 |
Sign in to see all competitors of Morphosys Ag.
Sources: Morphosys Ag's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Morphosys Ag versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Morphosys Ag's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Tradeup Acquisition Corp | Named by the company | 85% |
| Abcellera Biologics Inc | Named by the company | 85% |
| Argenx Se | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Morphosys Ag's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Morphosys Ag's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.26 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Morphosys Ag's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Morphosys Ag | 651 | 504,377 | -401,621 |
| Akari Therapeutics Plc | 1,104,440 | - | -4,674,667 |
| Eli Lilly And Company | 1,034,082 | 1,593,316 | 534,224 |
| Johnson and Johnson | 645,992 | 695,518 | 149,411 |
| Beone Medicines Ltd | 550,872 | 510,686 | 54,642 |
| Abbvie Inc | 463,276 | 1,129,579 | 110,807 |
| PEERS TOTAL | 6,037,697 | 998,203 | 145,988 |
Morphosys Ag's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Johnson and Johnson | United States 57.42 % |
| Beone Medicines Ltd | United States 51.69 % |
| Merck and Co Inc | EMEA 23.60 % |
| Gilead Sciences Inc | United States 70.78 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Morphosys Ag's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (345 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 78.19 % | 63.93 % (avg) | +14.3 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | -81.93 % | -7.12 % (avg) | -74.8 pp |
| Capital Intensity (Capex / Revenue) | 0.15 % | 4.90 % (avg) | -4.7 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Morphosys Ag's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (345 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 24.9x | - |
| EV / EBITDA | - | 17.1x | - |
| P/B | 4.6x | 4.5x | +0.1x |
| Return on Equity | -378.24 % | industry aggregate | -391.64 % |
| Return on Invested Capital | -13.42 % | -2.85 % (avg) | -10.57 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Morphosys Ag's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue Growth | -43.17 % | 37.95 % | -12.08 % |
| Operating Margin | - | -79.32 % | - |
| Return on Invested Capital | -21.11 % | -9.21 % | -13.42 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Morphosys Ag's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.15 % vs industry average 4.90 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Morphosys Ag's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Morphosys Ag's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Morphosys Ag's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Morphosys Ag falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Morphosys Ag's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+314.2% annualized vs trailing 12 months).
Weaknesses
- Return on equity 391.6 points below the industry aggregate.
Opportunities
- A meaningful share of tracked competitors (42.50 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Morphosys Ag's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Morphosys Ag | 0.60 | 3.08 | 5.01 |
| Akari Therapeutics Plc | 0.23 | 0.26 | 0.04 |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.16 | 0.75 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Morphosys Ag's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Morphosys Ag | Q4 2023 | -12.1 % | - |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| PEERS TOTAL | +12.0 % | -5.5 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Morphosys Ag's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Morphosys Ag | Q4 2023 | +30.3 % | -81.4 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
Morphosys Ag's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Morphosys Ag | - | - | - |
| Akari Therapeutics Plc | - | - | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 4.68% | 9.11% | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Morphosys Ag's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Morphosys Ag | - | 2.52 |
| Akari Therapeutics Plc | - | - |
| Eli Lilly And Company | 38.84 | 12.98 |
| Johnson and Johnson | 30.64 | 6.60 |
| Beone Medicines Ltd | 831.68 | 89.89 |
| Abbvie Inc | 73.90 | 7.20 |
| PEERS AVERAGE | 56.27 | 8.21 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.